| Ytd | 62.75% | |
| 1y | 60.65% |
| Open | 2.45 | Prev Close | 2.49 | Low | 2.45 | High | 2.51 | Mkt Cap | 235.44M |
| Vol | 50.83K | Avg Vol | 452.27K | EPS | 0.37 | P/E | 6.73 | Forward P/E | -13.82 |
| Beta | 2.76 | Short Ratio | 6.42 | Inst. Own | 14.97% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-05 | 50-d Avg | 2.37 | 200-d Avg | 2.06 | 1yr Est | 4.00 |
CGEN News
HOLON, Israel, July 21, 2026 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-st
HOLON, Israel, July 20, 2026 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN), a clinical-s
HOLON, Israel, June 18, 2026 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-st
Compugen Ltd. (CGEN) Discusses End-to-End AI-Driven Target Discovery in Immuno-Oncology Transcript
HOLON, Israel, June 11, 2026 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-st
HOLON, Israel, June 8, 2026 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-sta
Compugen (CGEN) is maintained at a "Buy" rating, driven by advancing clinical programs and upcoming
Compugen Ltd. (CGEN) Q1 2026 Earnings Call Transcript
Compugen NASDAQ: CGEN said it remains on track to report interim progression-free survival data in t
Compugen (CGEN) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimat
COM701 MAIA-ovarian trial actively enrolling patients across all clinical sites in the U.S., Israel,
HOLON, Israel, May 12, 2026 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-sta
HOLON, Israel, May 4, 2026 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN), a clinical-sta
HOLON, Israel, April 9, 2026 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-st
Compugen (NASDAQ: CGEN) executives used the company's fourth-quarter and full-year 2025 earnings cal
Compugen remains a 'Buy,' supported by pipeline progress, major pharma partnerships, and a cash runw
Compugen Ltd. (CGEN) Q4 2025 Earnings Call Transcript
Compugen (CGEN) came out with quarterly earnings of $0.6 per share, beating the Zacks Consensus Esti
Strengthened financial position through a non-dilutive transaction with AstraZeneca, monetizing a sm
HOLON, Israel, Feb. 19, 2026 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-st
Companies Reporting Before The Bell • NIO (NYSE:NIO) is estimated to report quarterly loss at $0.51
Companies Reporting Before The Bell • CorEnergy Infr Tr (NYSE:CORR) is estimated to report earnings
On Friday, 404 stocks made new 52-week lows.
On Thursday, 930 stocks hit new 52-week lows.
On Thursday, 1076 companies hit new 52-week lows.
On Wednesday, 340 stocks hit new 52-week lows.
During Monday's trading, 1214 companies set new 52-week lows.
On Friday, 1043 companies hit new 52-week lows.
On Friday, 209 companies set new 52-week lows.
Companies Reporting Before The Bell • CASI Pharmaceuticals (NASDAQ:CASI) is estimated to report
Companies Reporting Before The Bell • Mastercard Inc. (NYSE:MA) is expected to report quarterly ear
Stocks That Hit 52-Week Highs On Friday